Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06093672 · ClinicalTrials.gov registry record · Phase 3
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
A Phase 3 study of Polycythemia Vera, sponsored by Italfarma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06093672 is a Phase 3 study of Polycythemia Vera that is actively recruiting participants, run by Italfarma. The registered enrollment target is 220 participants, below the 330-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT06093672, a Phase 3 study of Polycythemia Vera, is actively recruiting participants, sponsored by Italfarma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
Conditions Studied
Interventions
- DRUG Hydroxyurea
- DRUG Givinostat
Study Locations (20)
Texas
- MD Anderson Cancer Center - Houston
- Texas Oncology (Webster) - USOR - Houston
- Texas Oncology-Denison Cancer Center - Sherman
Upper Austria
- Ordensklinikum Linz GmbH Elisabethinen - Linz
- Klinikum Wels-Grieskirchen GmbH - Wels
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Emad Ibrahim, MD, Inc - Redlands
Colorado
- US Oncology Inc - Englewood
Maryland
- American Oncology Partners of Maryland, PA - Bethesda
New York
- Icahn School of Medicine at Mount Sinai - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-03-26 |
| Est. Completion | 2026-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06093672
The ClinicalTrials.gov registry entry for NCT06093672 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 330-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (33% lower). The listed sponsor is Italfarma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polycythemia Vera appearing as the primary indexed condition, and to 2 interventions - of which Hydroxyurea is the first listed.
NCT06093672 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Texas, Upper Austria, Alabama.
Frequently Asked Questions
What is clinical trial NCT06093672 about?
NCT06093672 is a clinical study titled "Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera". The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
What is the current status of trial NCT06093672?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2024-03-26. Estimated completion is 2026-07.
What conditions does trial NCT06093672 study?
This clinical trial studies the following conditions: Polycythemia Vera.
What interventions are being tested in trial NCT06093672?
The interventions under investigation include: Hydroxyurea (DRUG), Givinostat (DRUG).
Who is sponsoring clinical trial NCT06093672?
This trial is sponsored by Italfarma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06093672 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RECRUITING · Phase 3
-
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
ACTIVE NOT RECRUITING · Phase 3
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.